Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
|||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Colorectal cancer, BRAF-mutated|BRAF-mutated colorectal cancer]] |
*[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]] | *[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. ''(Based on COLOMBUS)'' | *6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. ''(Based on COLOMBUS)'' | ||
| − | *4/9/2020: Approved in combination with cetuximab for the treatment of adult patients with metastatic [[ | + | *4/9/2020: Approved in combination with cetuximab for the treatment of adult patients with metastatic [[colorectal cancer (CRC)]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E mutation]], detected by an FDA-approved test, after prior therapy. ''(Based on BEACON CRC)'' |
==Also known as== | ==Also known as== | ||
| Line 17: | Line 17: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | |||
[[Category:BRAF inhibitors]] | [[Category:BRAF inhibitors]] | ||
| − | [[Category: | + | [[Category:Colorectal cancer medications]] |
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 14:57, 30 April 2022
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Binimetinib (Mektovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLOMBUS)
- 4/9/2020: Approved in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy. (Based on BEACON CRC)
Also known as
- Code name: LGX818
- Brand name: Braftovi